Xellar Biosystems (耀速科技, also trading as Xellar Technology) is a Chinese biotech building an AI + organ-on-a-chip closed-loop platform dubbed 3D-Wet-AI for preclinical drug testing. Founded in 2021, it is the only Chinese company selected for the US FDA's program to validate new alternative methods (NAMs) replacing animal testing, and maintains strategic partnerships with XtalPi on quantum-AI drug design and with Korea's WOOJUNG BIO on hybrid human-OoC plus animal preclinical platforms.
1
Round
5
Tags
Apr 8, 2026
Latest raise
Funding activity · 1 round
Apr 8, 2026
CNY 29.2M
Series A
Led by China Life Equity Investment
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
